UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 50

Sortiert nach

The role of gut hormones and the hypothalamus in appetite regulation

Endocrine Journal, 2010, Vol.57(5), pp.359-372

2010

Volltextzugriff (PDF)

A glucagon analogue decreases body weight in mice via signalling in the liver

Scientific reports, 2021-11, Vol.11 (1), p.22577-7, Article 22577

2021

Volltextzugriff (PDF)

Resistance to lean mass gain in constitutional thinness in free‐living conditions is not overpassed by overfeeding

Journal of cachexia, sarcopenia and muscle, 2020-10, Vol.11 (5), p.1187-1199

2020

Volltextzugriff (PDF)

Investigation of Structure-Activity Relationships of Oxyntomodulin (Oxm) Using Oxm Analogs

Endocrinology (Philadelphia), 2009-04, Vol.150 (4), p.1712-1722

2009

Volltextzugriff (PDF)

Investigating the Glucagon Receptor and Glucagon-Like Peptide 1 Receptor Activity of Oxyntomodulin-Like Analogues in Male Wistar Rats

Current therapeutic research, 2015-12, Vol.77 (C), p.111-115

2015

Volltextzugriff (PDF)

Differentiating constitutional thinness from anorexia nervosa in DSM 5 era

Psychoneuroendocrinology, 2017-10, Vol.84, p.94-100

2017

Volltextzugriff (PDF)

1798-P: Chronic Administration of a Long-Acting Glucagon Analogue Results in Enhanced Insulin Secretory Activity in a Directly-Observed Murine Model

Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)

2020

Volltextzugriff (PDF)

Increased food intake with oxyntomodulin analogues

Peptides (New York, N.Y. : 1980), 2015-11, Vol.73, p.95-100

2015

Volltextzugriff (PDF)

57-OR: Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Glycaemia and Body Weight in Obesity and Type 2 Diabetes: A Randomized, Single-Blinded Study

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Volltextzugriff (PDF)

Analogs of pancreatic polypeptide and peptide YY with a locked PP-fold structure are biologically active

Peptides (New York, N.Y. : 1980), 2013-01, Vol.39, p.6-10

2013

Volltextzugriff (PDF)

Hypoaminoacidemia underpins glucagon-mediated energy expenditure and weight loss

Cell reports. Medicine, 2022-11, Vol.3 (11), p.100810-100810, Article 100810

2022

Volltextzugriff (PDF)

Proglucagon-Derived Peptides Do Not Significantly Affect Acute Exocrine Pancreas in Rats

Pancreas, 2016-08, Vol.45 (7), p.967-973

2016

Volltextzugriff (PDF)

A role for metalloendopeptidases in the breakdown of the gut hormone, PYY 3-36

Endocrinology (Philadelphia), 2011-12, Vol.152 (12), p.4630-4640

2011

Volltextzugriff (PDF)

Pharmacokinetics, adverse effects and tolerability of a novel analogue of human pancreatic polypeptide, PP 1420

British journal of clinical pharmacology, 2012-02, Vol.73 (2), p.232-239

2012

Volltextzugriff (PDF)

A Role for Metalloendopeptidases in the Breakdown of the Gut Hormone, PYY3–36

Endocrinology (Philadelphia), 2011-12, Vol.152 (12), p.4630-4640

2011

Volltextzugriff (PDF)

Effect of Biased GLP-1/Glucagon Receptor Co-agonists on Insulin Secretion

Diabetes (New York, N.Y.), 2018-07, Vol.67 (Supplement_1)

2018

Volltextzugriff (PDF)

Degradation Paradigm of the Gut Hormone, Pancreatic Polypeptide, by Hepatic and Renal Peptidases

Endocrinology (Philadelphia), 2017-06, Vol.158 (6), p.1755-1765

2017

Volltextzugriff (PDF)

Chronic treatment with glucagon-like peptide-1 and glucagon receptor co-agonist causes weight loss-independent improvements in hepatic steatosis in mice with diet-induced obesity

Biomedicine & pharmacotherapy, 2024-07, Vol.176, p.116888, Article 116888

2024

Volltextzugriff (PDF)

Disconnect between signalling potency and in vivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists

Molecular metabolism (Germany), 2020-07, Vol.37, p.100991, Article 100991

2020

Volltextzugriff (PDF)

Divergent trajectories of cellular bioenergetics, intermediary metabolism and systemic redox status in survivors and non-survivors of critical illness

Redox biology, 2021-05, Vol.41, p.101907-101907, Article 101907

2021

Volltextzugriff (PDF)

The Effect of a Subcutaneous Infusion of GLP-1, OXM, and PYY on Energy Intake and Expenditure in Obese Volunteers

The journal of clinical endocrinology and metabolism, 2017-07, Vol.102 (7), p.2364-2372

2017

Volltextzugriff (PDF)

Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake

Diabetes (New York, N.Y.), 2014-11, Vol.63 (11), p.3711-3720

2014

Volltextzugriff (PDF)

Signalling, trafficking and glucoregulatory properties of glucagon‐like peptide‐1 receptor agonists exendin‐4 and lixisenatide

British journal of pharmacology, 2020-09, Vol.177 (17), p.3905-3923

2020

Volltextzugriff (PDF)

Abolishing β‐arrestin recruitment is necessary for the full metabolic benefits of G protein‐biased glucagon‐like peptide‐1 receptor agonists

Diabetes, obesity & metabolism, 2024-01, Vol.26 (1), p.65-77

2024

Volltextzugriff (PDF)

1 – 25 von 50

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(46)
Mit Volltextzugriff
(49)

Publikationsform

Artikel
(49)
Dissertationen
(1)

Sprache

Englisch
(50)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

The role of gut hormones and the hypothalamus in appetite regulation

A glucagon analogue decreases body weight in mice via signalling in the liver

Resistance to lean mass gain in constitutional thinness in free‐living conditions is not overpassed by overfeeding

Investigation of Structure-Activity Relationships of Oxyntomodulin (Oxm) Using Oxm Analogs

Investigating the Glucagon Receptor and Glucagon-Like Peptide 1 Receptor Activity of Oxyntomodulin-Like Analogues in Male Wistar Rats

Differentiating constitutional thinness from anorexia nervosa in DSM 5 era

1798-P: Chronic Administration of a Long-Acting Glucagon Analogue Results in Enhanced Insulin Secretory Activity in a Directly-Observed Murine Model

Increased food intake with oxyntomodulin analogues

57-OR: Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Glycaemia and Body Weight in Obesity and Type 2 Diabetes: A Randomized, Single-Blinded Study

Analogs of pancreatic polypeptide and peptide YY with a locked PP-fold structure are biologically active

Hypoaminoacidemia underpins glucagon-mediated energy expenditure and weight loss

Proglucagon-Derived Peptides Do Not Significantly Affect Acute Exocrine Pancreas in Rats

A role for metalloendopeptidases in the breakdown of the gut hormone, PYY 3-36

Pharmacokinetics, adverse effects and tolerability of a novel analogue of human pancreatic polypeptide, PP 1420

A Role for Metalloendopeptidases in the Breakdown of the Gut Hormone, PYY3–36

Effect of Biased GLP-1/Glucagon Receptor Co-agonists on Insulin Secretion

Degradation Paradigm of the Gut Hormone, Pancreatic Polypeptide, by Hepatic and Renal Peptidases

Chronic treatment with glucagon-like peptide-1 and glucagon receptor co-agonist causes weight loss-independent improvements in hepatic steatosis in mice with diet-induced obesity

Disconnect between signalling potency and in vivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists

Divergent trajectories of cellular bioenergetics, intermediary metabolism and systemic redox status in survivors and non-survivors of critical illness

The Effect of a Subcutaneous Infusion of GLP-1, OXM, and PYY on Energy Intake and Expenditure in Obese Volunteers

Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Body Weight and Glycemia in Obesity and Prediabetes/Type 2 Diabetes: A Randomized, Single-Blinded, Placebo-Controlled Study

Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake

Signalling, trafficking and glucoregulatory properties of glucagon‐like peptide‐1 receptor agonists exendin‐4 and lixisenatide

Abolishing β‐arrestin recruitment is necessary for the full metabolic benefits of G protein‐biased glucagon‐like peptide‐1 receptor agonists

Suchergebnisse filtern